Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study

Papp, K; Warren, RB; Green, L; Reich, K; Langley, RG; Paul, C; Asahina, A; Johnson, L; Arora, V; Osuntokun, O; Lebwohl, M

Papp, K (通讯作者)，Alliance Clin Trials, Waterloo, ON N2J 1C4, Canada.

LANCET RHEUMATOLOGY, 2023; 5 (9): E542

Abstract

Background Risankizumab and guselkumab, inhibitors of the interleukin (IL)-23 p19 subunit, are approved for treatment of adult patients with moderate-......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索